How Is Myeloma Treatment Changing? Quadruplets, CAR-T, Bispecifics and New Therapies | IMS 2026

Claudio Cerchione, MD, of IRST Meldola, Italy discusses four-drug quadruplet therapy for newly diagnosed myeloma, including transplant-ineligible patients, at IMS 2026 in Glasgow. He explains why he believes quadruplets should be standard for nearly all newly diagnosed patients, with only a small group of very frail patients receiving three drugs instead. He also discusses why deep MRD-negative responses matter and how a small on-body injector could make treatment simpler and possibly closer to home.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction: Dr. Claudio Cerchione, IRST Meldola
0:10 Quadruplets Are Becoming the Standard of Care
1:01 A New Goal: Deep MRD Negativity
1:29 On-Body Injector: Simpler Subcutaneous Treatment
2:40 Why Quadruplets for Nearly Every Newly Diagnosed Patient
3:14 Relapsed Myeloma: Bispecifics, CAR-T, and Belantamab
4:18 Oral Options: CELMoDs and Selinexor
5:17 Customizing Therapy for Each Patient
6:04 What's Changing for Smoldering Myeloma
7:16 Risk Criteria and Treating Earlier